| Shear contributions to cell culture performance and product recovery in ATF and TFF perfusion systems S Wang, S Godfrey, J Ravikrishnan, H Lin, J Vogel, J Coffman Journal of Biotechnology 246, 52-60, 2017 | 111 | 2017 |
| VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia S Sher, E Whipp, J Walker, P Zhang, L Beaver, K Williams, S Orwick, ... Leukemia 37 (2), 326-338, 2023 | 15 | 2023 |
| Manipulation of the sodium‐potassium ratio as a lever for controlling cell growth and improving cell specific productivity in perfusion CHO cell cultures SB Wang, A Lee‐Goldman, J Ravikrishnan, L Zheng, H Lin Biotechnology and bioengineering 115 (4), 921-931, 2018 | 14 | 2018 |
| Characterization of LP-118, a novel small molecule inhibitor of Bcl-2 and Bcl-Xl in chronic lymphocytic leukemia resistant to venetoclax J Ravikrishnan, EM Muhowski, TH Lai, S Misra, DD Rohena, F Tan, ... Blood 138, 679, 2021 | 9 | 2021 |
| Evaluation of allogeneic and autologous membrane-bound IL-21–expanded NK cells for chronic lymphocytic leukemia therapy M Yano, C Sharpe, JR Lance, J Ravikrishnan, K Zapolnik, X Mo, ... Blood Advances 6 (20), 5641-5654, 2022 | 8 | 2022 |
| Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia EM Muhowski, J Ravikrishnan, B Gordon, L Yu, S Misra, B Walker, ... Journal of Hematology & Oncology 15 (1), 166, 2022 | 6 | 2022 |
| HDAC1 regulates the chromatin landscape to control transcriptional dependencies in chronic lymphocytic leukemia TH Lai, HG Ozer, P Gasparini, G Nigita, R Distefano, L Yu, J Ravikrishnan, ... Blood Advances 7 (12), 2897-2911, 2023 | 4 | 2023 |
| HSP90 inhibition depletes DNA repair proteins to sensitize acute myelogenous leukemia to nucleoside analog chemotherapeutics TH Lai, S Mitchell, PJ Wu, S Orwick, C Liu, J Ravikrishnan, J Woyach, ... Leukemia & lymphoma 60 (9), 2308-2311, 2019 | 4 | 2019 |
| Targeting venetoclax resistant CLL using a protac-based BCL-2/BCL-XL degrader D Diaz Rohena, B Slawin, J Ravikrishnan, C Liu, W Hu, P Zhang, ... Blood 140 (Supplement 1), 497-498, 2022 | 3 | 2022 |
| Role of mutant p53 in the progression of chronic lymphocytic leukemia J Ravikrishnan, TH Lai, E Muhowski, L Brinton, K Williams, A Thompson, ... Blood 134, 2526, 2019 | 3 | 2019 |
| Enriched Signalling Pathways in Venetoclax-Relapsed Chronic Lymphocytic Leukemia (CLL) Cells and Targeting Using a Protac-Based Bcl-2/Bcl-Xl Degrader DD Rohena, AP Cuesta, B Slawin, J Ravikrishnan, C Liu, C Williams, ... Blood 142, 4195, 2023 | 1 | 2023 |
| MS-553, a Selective PKC-ß inhibitor inhibits BCR signaling and synergizes with Venetoclax for the treatment of high risk CLL J Singh, D Diaz Rohena, C Liu, B Slawin, J Ravikrishnan, N Jain, ... Blood 140 (Supplement 1), 9857-9858, 2022 | 1 | 2022 |
| P1269: VIP152 Is a Novel CDK9 Inhibitor with Improved Selectivity, Target Modulation, and Cardiac Safety in Patients with Lymphoma M Frigault, S Sher, J Ravikrishnan, R Izumi, J Ware, H Wong, A Johnson, ... HemaSphere 6, 1154-1155, 2022 | 1 | 2022 |
| HDAC1 regulates the chromatin landscape to establish transcriptional dependencies in chronic lymphocytic leukemia TH Lai, HG Ozer, P Gasparini, G Nigita, R Destefano, L Yu, ... bioRxiv, 2020.08. 03.232561, 2020 | 1 | 2020 |
| The Protein Kinase C Inhibitor MS-553 for the treatment of chronic lymphocytic leukemia EM Muhowski, AM Lehman, SD Reiff, J Ravikrishnan, R Mantel, S Misra, ... Blood 134, 2077, 2019 | 1 | 2019 |
| Development of highly intensified cell culture perfusion media and process with tremendous productivity potential, while having a low cell bleed requirement for maintaining an … H Lin, S Wang, D Ogawa, L Zheng, J Ravikrishnan, J Coffman | 1 | 2017 |
| Targeting Covalent and Non-Covalent Btki-Resistant CLL Using the Dual Irreversible/Reversible 4 th Generation BTK Inhibitor LP-168 B Gordon, E Muhowski, J Ravikrishnan, S Benrashid, A Mitchell, A He, ... Blood 142, 416, 2023 | | 2023 |
| The PKC-β Inhibitor MS-553 Displays Preclinical Efficacy in BTK Inhibitor Resistant Chronic Lymphocytic Leukemia B Gordon, E Muhowski, J Ravikrishnan, S Thangavadivel, S Benrashid, ... Blood 142, 2260, 2023 | | 2023 |
| PRMT5 Inhibition Alters Mitochondrial Dynamics in Mantle Cell Lymphoma Creating Vulnerability to BH3 Mimetic Compounds C Hinterschied, F Brown, J Ravikrishnan, JB Helmig-Mason, KR Harrison, ... Blood 140 (Supplement 1), 3118-3119, 2022 | | 2022 |
| Concentrated perfusion medium J Coffman, H Lin, T Luman, D Ogawa, J Ravikrishnan, H Tessman, ... US Patent App. 17/763,723, 2022 | | 2022 |
